It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Exelixis and Merck & Co. have inked a deal to study Exelixis' investigational drug zanzalintinib in combination with a pair of Merck's cancer drugs. The companies in Wednesday said the agreement ...

(RTTNews) - Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development collaboration to evaluate the combination of Exelixis ...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility ...

Technical indicators and charts suggest high risk for Merck, with the stock repeatedly breaking down. See why I rate MRK ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock prices are usually driven by a company’s ...